Close Menu

More articles about Infectious Disease

Biosearch said it is the first to license the CDC influenza signatures, and that it will manufacture and sell oligonucleotides bearing the H1N1 and influenza A sub-typing signatures.

The guidance document is intended to help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus, and provides information regarding filing for Emergency Use Authorization.

Using Sanger and second-generation sequencing approaches, researchers re-sequenced Mycobacterium leprae strains from Brazil, Thailand, and the US.

Gen-Probe got the EUA for a test made by Prodesse for detecting H1N1.

The company also remains on track with its more advanced familial adenomatous polyposis drug and plans to file within the next two weeks an investigational new drug application to begin testing the therapy in humans.

A Quest official said that the partnership with 3M is in line with its goal to move testing for influenza and other respiratory viruses "away from the reference labs and into the hospital labs."

A Roche official said that a "very substantial" portion of the 24 percent growth in qPCR and NAP systems could be attributed to H1N1, with the largest growth in instruments.

The newest authorization allows testing on 3M's molecular diagnostic system.

BD and Tyrian ended their partnership to develop a point-of-care diagnostic for active tuberculosis because of an inability to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.

The company will collaborate with UC Davis to develop a test for eight microbes that cause sepsis in burn and wound patients.

The company said it is working with the City of Hope to investigate the vector-based delivery of an anti-HIV RNA cocktail composed of pHIV7, an shRNA targeting an exon in HIV-1 tat/rev, and a Tar decoy.

Last week's ruling "is a complete victory for Roche," an attorney for the company told GenomeWeb Daily News.

The agreement covers systems for HIV and hepatitis B management.

The company will use $2.2 million to develop a PCR-based multiple flu test.

Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.

The $600,000 award also strengthens Inviragen's ties to UW-Madison. The company's CSO maintains an academic appointment and a research lab within the School of Veterinary Medicine, which has collaborated with Inviragen on other projects.

Biron will market and distribute the Warnex H1N1 flu diagnostic to industrial customers.

The companies have now “put together the final project plan, budgets, and agreements” for the HBV effort, according to Benitec’s CEO.

The recommendations cover performance for studies, detection, repeatability, and other practices.

In an interview with Pharmacogenomics Reporter this week, Hakan Sakul provided a snapshot of Pfizer's efforts in personalized medicine, the company's stance on regulatory issues, and its overall focus on "omics"-guided medicine.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.